Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1837507rdf:typepubmed:Citationlld:pubmed
pubmed-article:1837507lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:1837507lifeskim:mentionsumls-concept:C0178665lld:lifeskim
pubmed-article:1837507lifeskim:mentionsumls-concept:C0011847lld:lifeskim
pubmed-article:1837507lifeskim:mentionsumls-concept:C0124025lld:lifeskim
pubmed-article:1837507pubmed:issue9lld:pubmed
pubmed-article:1837507pubmed:dateCreated1992-2-24lld:pubmed
pubmed-article:1837507pubmed:abstractTextIslet cell cytoplasmic antibodies were determined in 85 individuals 60 to 74 years old with fasting hyperglycaemia, in 65 patients with cystic fibrosis, in 113 patients with pancreatitis, in 21 patients with Turner's phenotype, and in 135 first-degree relatives of patients with Type 1 (insulin-dependent) diabetes. Islet cell antibodies were absent in all 60 to 74-year-old subjects with fasting hyperglycaemia detected by screening, and who did not require insulin treatment within 3 years. Islet cell antibodies were also absent in all patients with pancreatitis, cystic fibrosis, or Turner's phenotype. Islet cell antibodies were detected in 2 out of 135 (1.5%) first-degree relatives of new Type 1 diabetic patients, and in 1 out of 371 (0.3%) non-diabetic control subjects. During 12 years of follow-up 1 of the 2 first-degree relatives with islet cell antibodies and the only positive control developed Type 1 diabetes. It is suggested that islet cell antibodies are primarily associated with Type 1 diabetes and not with other disorders of glucose tolerance.lld:pubmed
pubmed-article:1837507pubmed:languageenglld:pubmed
pubmed-article:1837507pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1837507pubmed:citationSubsetIMlld:pubmed
pubmed-article:1837507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1837507pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1837507pubmed:statusMEDLINElld:pubmed
pubmed-article:1837507pubmed:monthNovlld:pubmed
pubmed-article:1837507pubmed:issn0742-3071lld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:LernmarkAAlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:NerupJJlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:ChristyMMlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:LarsenSSlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:HeinzeEElld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:MarnerBBlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:DamsgaardE...lld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:Mandrup-Pouls...lld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:GarneSSlld:pubmed
pubmed-article:1837507pubmed:authorpubmed-author:BilleGGlld:pubmed
pubmed-article:1837507pubmed:issnTypePrintlld:pubmed
pubmed-article:1837507pubmed:volume8lld:pubmed
pubmed-article:1837507pubmed:ownerNLMlld:pubmed
pubmed-article:1837507pubmed:authorsCompleteNlld:pubmed
pubmed-article:1837507pubmed:pagination812-6lld:pubmed
pubmed-article:1837507pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:meshHeadingpubmed-meshheading:1837507-...lld:pubmed
pubmed-article:1837507pubmed:year1991lld:pubmed
pubmed-article:1837507pubmed:articleTitleIslet cell cytoplasmic antibodies (ICA) in diabetes and disorders of glucose tolerance.lld:pubmed
pubmed-article:1837507pubmed:affiliationHagedorn Research Laboratory, Gentofte, Denmark.lld:pubmed
pubmed-article:1837507pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1837507pubmed:publicationTypeComparative Studylld:pubmed